Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29740540
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29740540
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Front+Oncol
2018 ; 8
(ä): 126
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Signaling Pathways Regulating Redox Balance in Cancer Metabolism
#MMPMID29740540
De Santis MC
; Porporato PE
; Martini M
; Morandi A
Front Oncol
2018[]; 8
(ä): 126
PMID29740540
show ga
The interplay between rewiring tumor metabolism and oncogenic driver mutations is
only beginning to be appreciated. Metabolic deregulation has been described for
decades as a bystander effect of genomic aberrations. However, for the biology of
malignant cells, metabolic reprogramming is essential to tackle a harsh
environment, including nutrient deprivation, reactive oxygen species production,
and oxygen withdrawal. Besides the well-investigated glycolytic metabolism, it is
emerging that several other metabolic fluxes are relevant for tumorigenesis in
supporting redox balance, most notably pentose phosphate pathway, folate, and
mitochondrial metabolism. The relationship between metabolic rewiring and mutant
genes is still unclear and, therefore, we will discuss how metabolic needs and
oncogene mutations influence each other to satisfy cancer cells' demands.
Mutations in oncogenes, i.e., PI3K/AKT/mTOR, RAS pathway, and MYC, and tumor
suppressors, i.e., p53 and liver kinase B1, result in metabolic flexibility and
may influence response to therapy. Since metabolic rewiring is shaped by
oncogenic driver mutations, understanding how specific alterations in signaling
pathways affect different metabolic fluxes will be instrumental for the
development of novel targeted therapies. In the era of personalized medicine, the
combination of driver mutations, metabolite levels, and tissue of origins will
pave the way to innovative therapeutic interventions.